evaluation of [18f]mni-777 pet as a marker of tau pathology in subjects with tauopathies compared to healthy subjects

Conditions: Alzheimer's Disease (AD); Parkinson's Disease (PD); Chronic Traumatic Encephalopathy (CTE); Progressive Supranuclear Palsy (PSP); Frontal Temporal Dementia (FTD); Pick's Disease; Tauopathies

Summary: the goal of this study is to assess \[18f\]mni-777 pet imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: alzheimer's disease (ad),parkinson's disease (pd) progressive supranuclear palsy (psp), chronic traumatic encephalopathy (cte) and frontal temporal dementia (ftd) and age- and gender-matched healthy subjects.


Eligibility criteria:
inclusion criteria: for all subjects: * written informed consent or assent is obtained. * willing and able to cooperate with study procedures. * for females, non-child bearing potential or negative urine pregnancy test on day of \[18f\]mni-777 injection. alzheimer disease subjects: * the participant is 50 years or older. * participants have a clinical diagnosis of alzheimer's disease based on national institute of neurological and communicative disorders and stroke/alzheimer's disease and related disorders association (nincds/adrda) criteria (mckann, 1984) * modified hachinski ischemia scale score of ≤ 4. parkinson's disease subjects: * the participant is 30 years or older. * participants have a clinical diagnosis of pd based on the uk brain bank criteria (hughes, et al., 1982). * the duration of diagnosis of pd is \<20 years prior to the imaging visit * pd subjects must be on stable doses of medications for a period of at least 30 days prior to the imaging visit. * treatment with dopamine replacement therapies or other symptomatic therapies for pd is permitted; however, subjects must be on a stable dose of medications 30 days prior to the imaging visit. progressive supranuclear palsy subjects: * the participant is 30 years or older. * participants have a clinical diagnosis of psp based on national institute of neurological disorders and stroke/ (ninds) and the society for psp (spsp) criteria (litvan, et al. 1996). chronic traumatic encephalopathy subjects: * the participant is 18 years or older. * subjects with a diagnosis of probable cte based on a prior history of repetitive brain trauma and at least one concussion, and a current mood disorder (depression, apathy, irritability, suicidal ideation), cognitive symptoms (memory loss, impaired executive function) or behavioral symptoms (disinhibition, aggression and increased violence) (jordan, 2013). frontal temporal dementia/pick's disease subjects: * the participant is 50 years or older. * participants have a clinical diagnosis of ftd based on consensus for clinical diagnosis of frontotemporal dementia (neary, et al., 1998) healthy control subjects: * the participant is 18 - 85 years old. * negative history of neurological or psychiatric illness based on evaluation by a research physician. * mmse score must be 29 or above. exclusion criteria: all subjects will be excluded from participation for the following reasons: * the subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness. * the subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery). * the subject has evidence of a structural lesion on mri that may interfere with interpretation of pet imaging. * the subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. * the subject has participated in another clinical study within the previous 30 days. * pregnancy or women who are nursing or breastfeeding

Keywords: alzheimer's disease (ad) parkinson's disease (pd) progressive supranuclear palsy (psp) chronic traumatic encephalopathy (cte) frontal temporal dementia (ftd) pick's disease tauopathies